Italian regional health authority contributing clinical data, patient cohorts, and real-world validation to European cancer screening, palliative care, and public health research.
AUSL Reggio Emilia is a regional public health authority in Emilia-Romagna, Italy, that runs hospitals, clinics, and community health services for the Reggio Emilia district. In EU research, they contribute real-world clinical data, patient cohorts, and frontline healthcare expertise — particularly in cancer screening, palliative care, and pandemic response. Their value lies in being a large-scale healthcare provider that can test interventions directly in routine clinical practice, bridging the gap between research protocols and actual patient care. They bring population-level health data and the infrastructure to run clinical trials within an active public health system.
MyPeBS (risk-stratified breast cancer screening with genetics/polymorphisms) and CBIG-SCREEN (cervical cancer screening for vulnerable women) show sustained investment in population-based cancer detection.
DIAdIC (psychoeducational support for advanced cancer patients and caregivers) and BETTER-B (breathlessness treatment in palliative care) demonstrate deep engagement in supportive care research.
ORCHESTRA connected European cohorts for SARS-CoV-2 research, contributing population-based study data and epidemiological expertise.
STOPSTORM explores stereotactic radiotherapy for ventricular tachycardia — a newer clinical direction combining cardiology with radiation oncology.
CBIG-SCREEN targets vulnerable women with equitable screening approaches, and ORCHESTRA studied fragile populations during COVID-19, showing consistent attention to health disparities.
In their early H2020 period (2017–2019), AUSL RE focused on two pillars: personalized cancer screening using genetic risk scores (MyPeBS) and psychosocial support for advanced cancer patients and their caregivers (DIAdIC). From 2020 onward, their focus broadened to include pandemic preparedness (ORCHESTRA), health equity in screening for marginalized groups (CBIG-SCREEN), and cardiac radiotherapy (STOPSTORM). The shift shows a move from individual patient-level interventions toward population-level health challenges — cost-effectiveness, equity, and system-wide preparedness have become recurring themes.
AUSL RE is moving toward cost-effectiveness analysis, health equity for underserved populations, and system-level preparedness — making them a strong partner for public health implementation research.
AUSL RE operates exclusively as a participant or third party — they have never coordinated an H2020 project, which is typical for clinical healthcare providers who contribute patient data and clinical sites rather than leading research design. With 145 unique partners across 30 countries, they integrate into large, multinational consortia where their role is to provide real-world clinical validation. This makes them a reliable, low-friction partner: they know how to operate within big consortia and deliver clinical data on schedule.
With 145 consortium partners across 30 countries, AUSL RE has a remarkably wide network for a regional health authority, reflecting participation in large pan-European clinical trials and cohort studies. Their reach spans well beyond Italy into a truly continental network.
Unlike university hospitals that focus on basic research, AUSL RE is a frontline public health provider — they can offer access to real patient populations, routine clinical workflows, and population-level screening data that academic centers often lack. Their combination of cancer screening, palliative care, and pandemic response expertise in a single institution is uncommon. For consortium builders, they solve a common problem: finding a partner who can test research outcomes in everyday healthcare delivery, not just controlled lab settings.
